Samsung Medical Center
| République de Corée | Turquie | Espagne | |
| Une greffe de moelle osseuse | de $55,000 | de $36,000 | de $71,782 |
| Transplantation allogénique de moelle osseuse provenant d'un donneur non apparenté | de $145,000 | de $80,000 | de $150,000 |
| Transplantation allogénique de moelle osseuse d'un donneur apparenté | de $75,000 | de $65,000 | de $13,942 |
| Radiothérapie | de $12,500 | de $6,000 | de $5,000 |
| Greffe de moelle osseuse autologue | de $42,000 | de $31,500 | de $40,000 |
Bookimed ne rajoute pas de frais pour les traitements de Oncologie pédiatrique. Les tarifs proviennent des listes de prix officielles des cliniques. Vous payez directement à la clinique pour votre traitement à votre arrivée dans le pays.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans le traitement de Oncologie pédiatrique et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de traitement de Oncologie pédiatrique.
Seoul National University Hospital (SNUH), Asan Medical Center, and Samsung Medical Center are the premier institutions for pediatric oncology in South Korea. These JCI-accredited centers manage over 1,000 cases annually. They offer advanced therapies like proton beam treatment and CAR T-cell therapy for complex childhood cancers.
Bookimed Expert Insight: Data from South Korea's top-tier hospitals show a significant trend toward complete digitalization. For example, Seoul National University Hospital has been fully digital since 2004. This level of integration allows for faster multidisciplinary reviews. It ensures that pediatric patients receive highly coordinated care across surgical and radiation departments.
Patient Consensus: Families emphasize contacting international departments early for English support. They also suggest verifying surgeons through the Korean Society of Pediatric Hematology/Oncology for peace of mind.
The 5-year survival rate for childhood cancer in South Korea is approximately 85%. This reflects a significant improvement from 56% in the mid-1990s. Leading facilities like Seoul National University Hospital (SNUH) report the highest statistics for cancer treatment in the country.
Bookimed Expert Insight: The high survival rates in Seoul are tied to massive patient volumes and specialization. For example, Asan Medical Center treats 11,000+ outpatients daily. This scale allows doctors like Dr. Kang, Hyoung Jin to manage rare pediatric cases frequently. Such experience leads to refined protocols and better outcomes in complex oncology cases.
Patient Consensus: Parents note that early screening and rapid access to advanced immunotherapies are key factors. They also emphasize using translator apps to manage logistics despite the high clinical success rates.
Advanced pediatric tumor treatments in the Republic of Korea include CAR T-cell therapy, proton beam radiation, and robotic surgery. Specialized centers like Seoul National University Hospital (SNUH) and Samsung Medical Center integrate these with bone marrow transplantation. These technologies prioritize high efficacy while reducing long-term toxicity for developing children.
Bookimed Expert Insight: South Korea's leading hospitals, such as Severance and Asan Medical Center, often combine massive patient volumes with specialized pediatric clinics. Our data shows that facilities serving over 1,000,000 patients annually typically offer ultra-fast entry into clinical trials. This speed is a critical advantage for families seeking advanced immunotherapy or targeted fusion-gene treatments.
Patient Consensus: Parents note that proton therapy is exceptionally effective for brain tumors like medulloblastoma because it causes almost no radiation injury. Many families emphasize that trial enrollment for new therapies happens much faster here than in many overseas protocols.
Children can enroll in South Korean clinical trials by meeting eligibility criteria and following Ministry of Food and Drug Safety guidelines. Legal guardians must provide written consent for minors under 19. Patients often provide assent starting at age 7 to confirm their willingness to participate.
Bookimed Expert Insight: Patient volume at centers like Seoul National University Hospital, which treats 10,700 patients daily, creates a high-density environment for rare pediatric trials. Our data shows these large facilities often house English-speaking investigators like Dr. Kang, Hyoung Jin. This linguistic accessibility significantly simplifies the complex screening process for international families.
Patient Consensus: Parents note that partnering with a coordinator to handle regulatory filings is vital for success. They emphasize starting the process 4–6 months early to manage visa requirements and medical record translations.
Children returning to school in the Republic of Korea receive support through the Special Education Promotion Act. This law mandates tailored academic plans and reduced hours. Major centers like Seoul National University Hospital (SNUH) provide clinical reports to trigger these legal protections for students.
Bookimed Expert Insight: Schools in South Korea typically approve accommodation requests within 1–2 weeks once the oncology discharge summary is submitted. This efficiency is much faster than in many Western systems. For families in rural areas, opting for government homeschooling vouchers is often more effective than local school integration.
Patient Consensus: Patients note it is helpful to arrange teacher-led classroom presentations early. This helps classmates understand physical changes like hair loss and prevents potential bullying during the first weeks of re-entry.
The Republic of Korea offers comprehensive long-term follow-up systems for pediatric cancer survivors through specialized survivorship clinics and a national registry. These programs monitor late effects and recurrence risk. Facilities like Seoul National University Hospital (SNUH) provide dedicated pediatric oncology expertise for lifelong tracking.
Bookimed Expert Insight: Data from top Seoul clinics shows a high volume of over 1,000,000 patients annually. This massive scale allows hospitals like Asan Medical Center to refine survival protocols. Their experience with 65,000+ yearly operations creates a robust database for predicting and managing late-stage treatment effects.
Patient Consensus: Patients note that children receive free neurocognitive and endocrine screenings even 10 years after treatment. They emphasize enrolling in the national registry early to ensure reminders for adulthood check-ups aren't missed.
Pediatric oncology in the Republic of Korea personalizes care through rapid genomic sequencing and AI-driven treatment mapping. Specialist centers like Seoul National University Hospital (SNUH) and Samsung Medical Center integrate international services with advanced diagnostics. Families receive tailored plans involving immunotherapy, proton therapy, and robotic surgery.
Bookimed Expert Insight: Hospitals with the KOIHA accreditation, such as Asan Medical Center, often have higher success rates for complex pediatric cases. Our data shows these centers manage over 65,000 operations annually. This high volume allows surgeons to refine techniques for rare childhood tumors that smaller clinics see less frequently.
Patient Consensus: Patients note it is helpful to upload genetic tests before arrival to speed up the treatment plan. Families appreciate that hospitals adapt daily care routines and offer meal options that respect cultural or religious needs.